Skip to main content

Maria Cristina Díaz de Heredia Rubio

I am a pediatrician specialized in pediatric hematology and oncology and in hematopoietic stem cell transplantation. My clinical and research activity focuses on blood disorders, leukemias, and other non-oncological hematological diseases, as well as on hematopoietic stem cell transplantation in children. Since 2005, I am the Head of the Pediatric Hematology Section and I lead the Hematopoietic Stem Cell Transplantation and Advanced Therapies Program within the Department of Pediatric Oncology and Hematology. I am committed to bringing the most innovative treatments to our patients. At the national level, I lead the pediatric group of the Spanish Group for Hematopoietic Transplantation (GETH) and the hematopoietic stem cell transplantation group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP), with the aim of improving the clinical outcomes of this procedure in children and adolescents. I am an active member of the board of the European pediatric hematopoietic stem cell transplantation group of the European Society for Blood and Marrow Transplantation (EBMT), and I actively participate in the SEHOP bone marrow failure working group. My commitment and dedication to hematopoietic stem cell transplantation and bone marrow failure syndromes have made me a national reference in these fields.

Institutions of which they are part

Predoctoral researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca
Head of Section
Paediatric Oncology and Haematology
Children's Hospital and Woman's Hospital

Maria Cristina Díaz de Heredia Rubio

Institutions of which they are part

Predoctoral researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca
Head of Section
Paediatric Oncology and Haematology
Children's Hospital and Woman's Hospital

I am a pediatrician specialized in pediatric hematology and oncology and in hematopoietic stem cell transplantation. My clinical and research activity focuses on blood disorders, leukemias, and other non-oncological hematological diseases, as well as on hematopoietic stem cell transplantation in children. Since 2005, I am the Head of the Pediatric Hematology Section and I lead the Hematopoietic Stem Cell Transplantation and Advanced Therapies Program within the Department of Pediatric Oncology and Hematology. I am committed to bringing the most innovative treatments to our patients. At the national level, I lead the pediatric group of the Spanish Group for Hematopoietic Transplantation (GETH) and the hematopoietic stem cell transplantation group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP), with the aim of improving the clinical outcomes of this procedure in children and adolescents. I am an active member of the board of the European pediatric hematopoietic stem cell transplantation group of the European Society for Blood and Marrow Transplantation (EBMT), and I actively participate in the SEHOP bone marrow failure working group. My commitment and dedication to hematopoietic stem cell transplantation and bone marrow failure syndromes have made me a national reference in these fields.

In terms of research, I am a member of the “Childhood Cancer and Blood Disorders” group at the Vall d’Hebron Research Institute (VHIR) and I lead the Hematopoietic Stem Cell Transplantation and Advanced Therapies Program within this group. I am the national coordinator of the international clinical trial ALL-SCT FORUM, with the objective to identify the optimal transplantation strategy in children and adolescents with acute lymphoblastic leukemia. In the field of advanced cellular therapies, I work on several innovative projects in gene therapy for congenital diseases, as well as on the use of mesenchymal cells and antigen-specific cytotoxic lymphocytes for the treatment of certain post-transplant complications.

Projects

ENABLING PERSONALIZED MEDICINE OF SICKLE CELL DISEASE PATIENTS BASED ON INTEGRATIVE DIAGNOSIS OF NEW GENERATION METHODOLOGIES

IP: M Mar Mañu Pereira
Collaborators: Pablo Velasco Puyó, Bárbara Tazón Vega, David Beneitez Pastor, Maria Cristina Díaz de Heredia Rubio, Adoración Blanco Alvarez, Thaïs Murciano Carrillo, Amira Idrizovic
Funding agency: Instituto de Salud Carlos III
Funding: 99220
Reference: PI20/01454
Duration: 01/01/2021 - 30/06/2025

TRASLACIÓN DE UN PRODUCTO DE INGENIERÍA TISULAR ALOGÉNICO CON MSC DE GELATINA DE WHARTON PARA EL TRATAMIENTO DE LA OSTEONECROSIS EN PACIENTES ONCOLÓGICOS PEDIÁTRICOS.

IP: Joaquim Vives Armengol
Collaborators: Roberto Vélez Villa, Nayana Joshi Jubert, Lluis Martorell Cedres, Maria Cristina Díaz de Heredia Rubio, Màrius Aguirre Canyadell, Irene Portas Torres, Raquel Cabrera Perez
Funding agency: Instituto de Salud Carlos III
Funding: 87120
Reference: PI19/01788
Duration: 01/01/2020 - 30/06/2024

Investigació translacional en càncer infantil (GRE)

IP: Josep Sánchez de Toledo Codina
Collaborators: Soledad Gallego Melcón, Aroa Soriano Fernández, Maria Cristina Díaz de Heredia Rubio, Miguel Segura Ginard, Anna Llort Sales, Raquel Hladun Alvaro, Laura Alonso Garcia, Josep Roma Castanyer
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 30000
Reference: 2014 SGR 660
Duration: 01/01/2014 - 31/12/2016

Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action (EUROFANCOLEN) Grant Agreement nº 305421

IP: Josep Sánchez de Toledo Codina
Collaborators: Jordi Barquinero Mañez, Maria Cristina Díaz de Heredia Rubio, Raquel Hladun Alvaro
Funding agency: EUROPEAN COMMISSION
Funding: 285000
Reference: EUROFANCOLEN_FP7HEALTH2012
Duration: 01/01/2013 - 31/12/2018

Related news

The European initiative Hope4Kids will strengthen and harmonise paediatric palliative care across Europe, with the aim of ensuring comprehensive, high-quality care for all children living with life-threatening or life-limiting conditions.

The initiative will enable young people aged 12 to 18 to collaborate with campus researchers in the design, development and communication of scientific projects, placing patients and families at the centre of the research process.

The REACH5 study confirms that the efficacy and safety results observed in previous studies are maintained after three years of follow-up.

Related professionals

Pascual González, Gabriel

Pascual González, Gabriel

Research assistant
Cardiovascular Diseases
Read more
Falcó Roget, Anna

Falcó Roget, Anna

Research technician
Infectious Diseases
Read more
Bragulat Arevalo, Mireia

Bragulat Arevalo, Mireia

Research technician
Cardiovascular Diseases
Read more
Guri Lopez, Thais

Guri Lopez, Thais

Research assistant
Shock, Organ Dysfunction and Resuscitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.